Eterna Therapeutics announced promising preclinical results for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer by activating the immune system. In a study conducted at MD Anderson, ...

More than 300,000 women are diagnosed with ovarian cancer globally each year. The four-year clinical trial across 15 ...

Imunon, Inc. ( ($IMNN) ) has released its Q3 earnings. Here is a breakdown of the information Imunon, Inc. presented to its investors. IMUNON, ...

Received FDA Fast Track designation for stenoparib in advanced ovarian cancerReported landmark median overall survival now exceeding 25 ...

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer ...

Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at ...

Novel drug combinations that improve outcomes, outstanding questions about treatment sequence, and encouraging results in chemotherapy resistant disease are among the ovarian cancer highlights ...

For decades, immune-based cancer therapies have offered hope but also risk, with powerful tumor-fighting effects often ...

A simple procedure during routine surgery could prevent thousands of Australian women from getting ovarian cancer.

AVAX Technologies, Inc. (USOTC: AVXT), a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV ...

April 14, 2011 — A meta-analysis of 61 studies that looked at the relationship between cancer and antidepressant use shows a "small but statistically significant" increase in the risk for breast and ...

(RTTNews) - Eterna Therapeutics (ERNA), a clinical-stage biotechnology company, on Tuesday announced positive preclinical data from a study evaluating its lead product, ERNA-101, for the treatment of ...